Explanipedia

The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial Open

S W M Lammers, Sandra M. E. Geurts, Karlijn Susanna Francisca Maria Hermans, Loes Kooreman, Astrid C P Swinkels , et al. · 2025

70-Gene signature-guided adjuvant systemic treatment adjustments in early-stage ER+ breast cancer patients: 7-year follow-up of a prospective multicenter cohort study Open

Eline E. F. Verreck, Anne Kuijer, Julia E. C. van Steenhoven, José H. Volders, Annette W.G. van der Velden , et al. · 2024

The efficacy of screening with FDG-PET/CT for distant metastases in breast cancer patients scheduled for neoadjuvant systemic therapy Open

Jetske L B Gunster, Frederieke van Duijnhoven, Astrid N. Scholten, Carolien H. Smorenburg, Vincent O. Dezentjé , et al. · 2024

Long-Term Outcomes of 1989 Immediate Implant-Based Breast Reconstructions: An Analysis of Risk Factors for Failure and Revision Surgery Open

Merel M. L. Kooijman, A.C.M. van Bommel, Frederieke van Duijnhoven, Astrid N. Scholten, Carolien H. Smorenburg , et al. · 2024

Background: Nipple- or skin-sparing mastectomy and immediate implant-based breast reconstruction (IBR) is potentially associated with long-term unfavorable outcomes, such as revision surgery and reconstruction failure. This large patient c…

The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer Open

S W M Lammers, Sandra M. E. Geurts, Irene E.G. van Hellemond, Astrid C P Swinkels, Carolien H. Smorenburg , et al. · 2023

Background Obesity has been associated with an adverse prognosis and reduced efficacy of endocrine therapy in patients with hormone receptor-positive (HR+) breast cancer (BC). This study determines the prognostic and predictive effect of b…

Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in <i>ERBB2</i>-Positive Metastatic Breast Cancer Open

Jens Huober, Patrik Weder, Karin Ribi, Beat Thürlimann, Jean‐Christophe Théry , et al. · 2023

Importance In ERBB2 (formerly HER2 )-positive metastatic breast cancer (MBC), combining trastuzumab and pertuzumab with taxane-based chemotherapy is the first line of standard care. Given that trastuzumab plus pertuzumab was proven effecti…

94MO The prognostic and predictive effect of BMI in postmenopausal HR+ breast cancer patients receiving (extended) endocrine therapy: DATA trial analysis Open

S.W.M. Lammers, Sandra M. E. Geurts, Irene E.G. van Hellemond, Astrid C P Swinkels, Carolien H. Smorenburg , et al. · 2023

This study determines the prognostic and predictive effect of body mass index (BMI) on the disease-free survival (DFS) of postmenopausal hormone receptor-positive (HR+) breast cancer patients who received (extended) endocrine therapy. Pati…

Extended adjuvant aromatase inhibition after sequential endocrine therapy in postmenopausal women with breast cancer: follow-up analysis of the randomised phase 3 DATA trial Open

Vivianne C. G. Tjan‐Heijnen, S W M Lammers, Sandra M. E. Geurts, Ingeborg J. H. Vriens, Astrid C P Swinkels , et al. · 2023

Comparable effectiveness of 45- and 20-min post-infusion scalp cooling time in preventing paclitaxel-induced alopecia — a randomized controlled trial Open

Rieneke T. Lugtenberg, Corina van den Hurk, Carolien H. Smorenburg, Linda Mosch, Danny Houtsma , et al. · 2022

The effect of trastuzumab on cardiac function in patients with <span>HER2</span>‐positive metastatic breast cancer and reduced baseline left ventricular ejection fraction Open

Nathalie I. Bouwer, Tessa G. Steenbruggen, Hánah N. Rier, Jos Kitzen, Carolien H. Smorenburg , et al. · 2022

We investigated the effect of trastuzumab on cardiac function in a real‐world historic cohort of patients with HER2‐positive metastatic breast cancer (MBC) with reduced baseline left ventricular ejection fraction (LVEF). Thirty‐seven patie…

Comparable effectiveness of 45-min and 20-min post-infusion scalp cooling time in preventing paclitaxel-induced alopecia – a randomized controlled trial Open

Rieneke T. Lugtenberg, Corina J. van den Hurk, Carolien H. Smorenburg, Linda Mosch, Danny Houtsma , et al. · 2022

Purpose Scalp cooling can prevent chemotherapy-induced alopecia (CIA). Previously, the post-infusion cooling time (PICT) could be successfully reduced in docetaxel-treated patients from 90 to 45 and 20 minutes. Therefore it seems plausible…

Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring? Open

Nathalie I. Bouwer, Tessa G. Steenbruggen, Joost van Rosmalen, Hánah N. Rier, Jos Kitzen , et al. · 2021

Purpose Patients with HER2-positive metastatic breast cancer (MBC) usually receive many years of trastuzumab treatment. It is unknown whether these patients require continuous left ventricular ejection fraction (LVEF) monitoring. We studie…

Multidisciplinary breast cancer guideline in the Netherlands: Modular revisions aiming for improved personalized breast cancer care Open

J. van Hoeve, Thijs van Vegchel, Désirée A. E. Hairwassers, Liesbeth Boersma, Inge-Marie Obdeijn , et al. · 2020

Background: In 2000 the first national evidence based guideline on screening and diagnostics for breast cancer was released. Two years later, in 2002, the first national multidisciplinary guideline for treatment followed. In 2008 these two…

Cryotherapy to prevent doxorubicin-associated oral mucositis Open

L. Brink-Mosch, Martijn M. Stuiver, Evelina Der, Carolien H. Smorenburg · 2020

Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial Open

Irene E.G. van Hellemond, Carolien H. Smorenburg, Petronella G.M. Peer, Astrid C P Swinkels, Caroline Seynaeve , et al. · 2020

Verschillen in borstkankerzorg: keuze van patient of een aanwijzing voor verbetering? Open

Kelly de Ligt, Sabine Siesling, Akkke Albada, Marc A.M. Mureau, Carolien H. Smorenburg · 2020

Impact of Second Opinions in Breast Cancer Diagnostics and Treatment: A Retrospective Analysis Open

Erik Heeg, Yasmin A. Civil, Marij A. Hillen, Carolien H. Smorenburg, Leonie A. E. Woerdeman , et al. · 2019

The impact of health symptoms on health-related quality of life in early-stage breast cancer survivors Open

Kelly M. de Ligt, M. Heins, Janneke Verloop, Nicole P. M. Ezendam, Carolien H. Smorenburg , et al. · 2019

Borstkankerzorg individueler met meer aandacht voor kwaliteit van leven Open

T. van Vegchel, Carolien H. Smorenburg, D. Hairwassers, Liesbeth Boersma, I.M. Obdeijn , et al. · 2019

Transformation of the National Breast Cancer Guideline Into Data-Driven Clinical Decision Trees Open

Mathijs P. Hendriks, Xander Verbeek, Thijs van Vegchel, Maurice J.C. van der Sangen, Luc J. A. Strobbe , et al. · 2019

PURPOSE The essence of guideline recommendations often is intertwined in large texts. This impedes clinical implementation and evaluation and delays timely modular revisions needed to deal with an ever-growing amount of knowledge and appli…

Patient-reported health problems and healthcare use after treatment for early-stage breast cancer Open

Kelly M. de Ligt, M. Heins, Janneke Verloop, Carolien H. Smorenburg, Joke C. Korevaar , et al. · 2019

Almost all patients experienced health problems up to five years after breast cancer diagnosis, with a range of complaints that were consistently present over time. Factors associated with the development of health problems are useful for …

Breast-Contour-Preserving Procedure as a Multidisciplinary Parameter of Esthetic Outcome in Breast Cancer Treatment in The Netherlands Open

Annnelotte van Bommel, P.E.R. Spronk, Marc A.M. Mureau, Sabine Siesling, Carolien H. Smorenburg , et al. · 2019

Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study Open

Irene E.G. van Hellemond, Carolien H. Smorenburg, Petronella G.M. Peer, Astrid C P Swinkels, Caroline Seynaeve , et al. · 2019

The phase III DATA study investigates the efficacy of adjuvant anastrozole (6 vs . 3 year) in postmenopausal women with breast cancer previously treated with 2–3 years of tamoxifen. This planned side‐study assessed patterns of care regardi…

Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy‐induced ovarian function failure Open

Irene E.G. van Hellemond, Ingeborg J. H. Vriens, Petronella G.M. Peer, Astrid C P Swinkels, Carolien H. Smorenburg , et al. · 2018

The DATA study (NCT00301457) compared 6 and 3 years of anastrozole in postmenopausal women with hormone receptor‐positive early breast cancer after 2–3 years of tamoxifen. Patients with chemotherapy‐induced ovarian function failure (CIOFF)…

Current decisions on neoadjuvant chemotherapy for early breast cancer: Experts’ experiences in the Netherlands Open

P.E.R. Spronk, Kelly M. de Ligt, A.C.M. van Bommel, Sabine Siesling, Carolien H. Smorenburg , et al. · 2018

Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer Open

Annette A. van Zweeden, C.J. van Groeningen, Richard J. Honeywell, Elisa Giovannetti, Rita Ruijter , et al. · 2018

Patients' experiences with decisions on timing of chemotherapy for breast cancer Open

Kelly M. de Ligt, P.E.R. Spronk, A.C.M. van Bommel, Marie-Jeanne T. F. D. Vrancken Peeters, Sabine Siesling , et al. · 2017

Variation in use of neoadjuvant chemotherapy in patients with stage III breast cancer: Results of the Dutch national breast cancer audit Open

P.E.R. Spronk, A.C.M. van Bommel, Sabine Siesling, Michel W.J.M. Wouters, Marie-Jeanne T. F. D. Vrancken Peeters , et al. · 2017

Impact of gene-expression profiling in patients with early breast cancer when applied outside the guideline directed indication area Open

K. Schreuder, Anne Kuijer, Emiel J. Rutgers, Carolien H. Smorenburg, T van Dalen , et al. · 2017

Breast magnetic resonance imaging use in patients undergoing neoadjuvant chemotherapy is associated with less mastectomies in large ductal cancers but not in lobular cancers Open

Ingeborg J. H. Vriens, Kristien Keymeulen, Marc B. I. Lobbes, A.C.M. van Bommel, Grard A. P. Nieuwenhuijzen , et al. · 2017

Carolien H. Smorenburg YOU? Author Swipe